Anchored in technology developed by MIT personnel and licensed from that institution addressing accurate and rapid identification of emerging viral diseases, E25Bio is developing a diagnostic test technology for point of care detection of dangerously infectious diseases. The latter include, for example, acute febrile illnesses affecting more than 700 million people annually. Febrile is the medical term for elevated body temperature (or a fever) constituting the body's natural reaction to invasion by an infectious disease or pathogens and includes active dengue, zika and chikungunya viruses. The firm's low-cost and accurate solution more effectively to facilitate epidemiologic predictions makes it among the first of its kind able to screen for active viruses and thereby enable a more rapid and accurate diagnosis of dangerous infectious diseases in time to receive potentially life-saving treatment.
